1,3-substituted cyclobutyl derivatives and uses thereof
Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof,
wherein:
W is C(═O) or absent;
X is N or N oxide;
Y is N or CH;
Z is NH, O or S;
A is CH 2 or absent;
L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C 6 -C 10 aryl, and 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S;
R A is at each occurrence independently selected from halo, —CN, C 1 -C 6 haloalkyl, C 1 -C 6 alkyl, SF 5 , C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxyl, C 1 -C 6 haloalkoxyl, 4- to 6-membered heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S, —(CH 2 ) p —NR 3 R 4 and —C(═O)—O—(C 1 -C 6 alkyl),
wherein the C 3 -C 6 cycloalkyl and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R A1 ;
R A1 is at each occurrence independently selected from halo and C 1 -C 6 haloalkyl;
R 1 is at each occurrence independently selected from hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, halo, C 1 -C 6 haloalkyl and NR 3 R 4 ,
wherein the C 1 -C 6 alkyl and C 1 -C 6 haloalkyl are each independently substituted with 0-4 R 1a ;
R 1a is at each occurrence independently selected from hydroxyl, NR 3 R 4 and —C(═O)—OH;
R 2 is selected from hydrogen and C 1 -C 6 alkyl;
R 3 is at each occurrence independently selected from hydrogen and C 1 -C 6 alkyl;
R 4 is at each occurrence independently selected from —SO 2 R 5 , hydrogen, —C(═O)—(C 1 -C 6 alkyl) and C 1 -C 6 alkyl;
R 5 is at each occurrence independently selected from NH 2 and C 1 -C 6 alkyl;
n is 0, 1, 2, 3 or 4;
m is 0, 1, 2, 3, 4 or 5;
p is 0, 1 or 2.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
W is C(═O) or absent;
X is N or N oxide;
Y is CH;
Z is NH, O or S;
A is CH 2 or absent;
L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C 6 -C 10 aryl and 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S;
R A is at each occurrence independently selected from halo, —CN, C 1 -C 6 haloalkyl, C 1 -C 6 alkyl, SF 5 , C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxyl, C 1 -C 6 haloalkoxyl, 4- to 6-membered heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S and —(CH 2 ) p —NR 3 R 4 ,
wherein the C 3 -C 6 cycloalkyl and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R A1 ;
R A1 is at each occurrence independently selected from halo and C 1 -C 6 haloalkyl;
R 1 is at each occurrence independently selected from C 1 -C 6 alkyl, halo, C 1 -C 6 haloalkyl and NR 3 R 4 ,
wherein the C 1 -C 6 alkyl and C 1 -C 6 haloalkyl are each independently substituted with 0-4 R 1a ;
R 1a is at each occurrence independently selected from hydroxyl, NR 3 R 4 and —C(═O)—OH;
R 2 is selected from hydrogen and C 1 -C 6 alkyl;
R 3 is at each occurrence independently selected from hydrogen and C 1 -C 6 alkyl;
R 4 is at each occurrence independently selected from —SO 2 R 5 , hydrogen, —C(═O)—(C 1 -C 6 alkyl) and C 1 -C 6 alkyl;
R 5 is at each occurrence independently selected from NH 2 and C 1 -C 6 alkyl;
n is 0, 1, 2, 3, 4;
m is 0, 1, 2, 3, 4 or 5;
p is 0, 1 or 2.
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof,
wherein
W is C(═O) or absent;
X is N or N oxide;
Y is CH;
Z is NH, O or S;
A is CH 2 or absent;
L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C 6 -C 10 aryl and 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S;
R A is at each occurrence independently selected from halo, —CN, C 1 -C 6 haloalkyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxyl, C 1 -C 6 haloalkoxyl, 4- to 6-membered heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S and —(CH 2 ) p —NR 3 R 4 ,
wherein the C 3 -C 6 cycloalkyl and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R A1 ;
R A1 is at each occurrence independently selected from halo and C 1 -C 6 haloalkyl;
R 1 is at each occurrence independently selected from C 1 -C 6 alkyl, halo, C 1 -C 6 haloalkyl and NH 2 ,
wherein the C 1 -C 6 alkyl and C 1 -C 6 haloalkyl are each independently substituted with 0-4 R 1a ;
R 1a is at each occurrence independently selected from hydroxyl, NR 3 R 4 and —C(═O)—OH;
R 2 is selected from hydrogen and C 1 -C 3 alkyl;
R 3 is at each occurrence independently selected from hydrogen and C 1 -C 6 alkyl;
R 4 is at each occurrence independently selected from —SO 2 R 5 , hydrogen, —C(═O)—(C 1 -C 6 alkyl) and C 1 -C 6 alkyl;
R 5 is at each occurrence independently selected from NH 2 and C 1 -C 6 alkyl;
n is 0, 1, 2 or 3;
m is 0, 1, 2, 3 or 4;
p is 0, 1 or 2.
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof,
wherein
W is absent;
X is N;
Y is CH;
Z is NH, O or S;
A is absent;
L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C 6 -C 10 aryl, and 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S;
R A is at each occurrence independently selected from halo, —CN, C 1 -C 6 haloalkyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkoxyl, 4- to 6-membered heterocyclyl having 1-2 heteroatoms independently selected from N, O, and S and —(CH 2 ) p —NR 3 R 4 ,
wherein the C 3 -C 6 cycloalkyl and 4- to 6-membered heterocyclyl are each independently substituted with 0-4 R A1 ;
R A1 is at each occurrence independently selected from halo and C 1 -C 6 haloalkyl;
R 1 is at each occurrence independently selected from C 1 -C 6 alkyl, halo, C 1 -C 6 haloalkyl,
wherein the C 1 -C 6 alkyl and C 1 -C 6 haloalkyl are each independently substituted with 0-4 R 1a ;
R 1a is at each occurrence independently selected from hydroxyl, NR 3 R 4 and —C(═O)—OH;
R 2 is selected from hydrogen and C 1 -C 3 alkyl;
R 3 is at each occurrence independently selected from hydrogen and C 1 -C 6 alkyl;
R 4 is at each occurrence independently selected from —SO 2 R 5 , hydrogen, —C(═O)—(C 1 -C 6 alkyl) and C 1 -C 6 alkyl;
R 5 is at each occurrence independently selected from NH 2 and C 1 -C 6 alkyl;
n is 0, 1, 2 or 3;
m is 0, 1, 2, 3 or 4;
p is 0, 1 or 2.
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof,
wherein R A is selected from fluoro, chloro, —CN, C 1 -C 6 fluoroalkyl (e.g., C 1 -C 3 fluoroalkyl), C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 fluoroalkoxyl and 4-membered heterocyclyl having 1 oxygen atom,
wherein the C 3 -C 6 cycloalkyl and the 4-membered oxygen containing heterocyclyl are each independently substituted with 0-3 R A1 , and wherein R A1 is at each occurrence independently selected from halo and C 1 -C 6 haloalkyl.
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof,
wherein L is selected from C 6 -C 10 aryl, 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, and 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S selected from
wherein the C 6 -C 10 aryl, 6- to 10-membered partially saturated heterocyclyl and 5- to 10-membered heteroaryl are each independently substituted with 0-4 R A , and wherein R A is defined according to claim 1 .
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof,
wherein L is selected from 6- to 10-membered partially saturated heterocyclyl having 1-3 heteroatoms independently selected from N, O, and S, 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, and C 6 -C 10 aryl selected from phenyl and naphthyl,
wherein the 6- to 10-membered partially saturated heterocyclyl, 5- to 10-membered heteroaryl, phenyl and naphthyl are each independently substituted with 0-4 R A , and wherein R A is defined according to claim 1 .
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is selected from 5- to 10-membered heteroaryl having 1-3 heteroatoms independently selected from N, O, and S, C 6 -C 10 aryl and 6- to 10-membered partially saturated heterocyclyl selected from
wherein the 5- to 10-membered heteroaryl, C 6 -C 10 aryl and 6- to 10-membered partially saturated heterocyclyl are each independently substituted with 0-4 R A , and wherein R A is defined according to claim 1 .
9. The compound of claim 1 or a pharmaceutically acceptable salt thereof,
wherein R 1 is at each occurrence independently selected from C 1 -C 6 alkyl, halo, C 1 -C 6 haloalkyl and NH 2 ,
wherein the C 1 -C 6 alkyl and C 1 -C 6 haloalkyl are each independently substituted with 0-4 R 1a ,
wherein R 1a is at each occurrence independently selected from hydroxyl and NR 3 R 4 .
10. The compound of claim 1 or a pharmaceutically acceptable salt thereof,
wherein
W is absent;
X is N;
Y is CH;
Z is O;
A is absent;
L is C 6 -C 10 aryl;
R A is at each occurrence independently selected from halo, —CN, C 1 -C 6 haloalkyl, C 1 -C 6 alkyl;
R 1 is at each occurrence independently selected from C 1 -C 6 alkyl, halo and C 1 -C 6 haloalkyl,
wherein the C 1 -C 6 alkyl and C 1 -C 6 haloalkyl are each independently substituted with 0-4 R 1a ;
R 1a is at each occurrence independently selected from hydroxyl and NR 3 R 4 ;
R 2 is selected from hydrogen and C 1 -C 3 alkyl;
R 3 is at each occurrence independently selected from hydrogen and C 1 -C 6 alkyl;
R 4 is at each occurrence independently selected from —SO 2 R 5 , hydrogen and C 1 -C 6 alkyl;
R 5 is at each occurrence independently selected from NH 2 and C 1 -C 6 alkyl;
n is 1, 2 or 3;
m is 0, 1, 2 or 3.
11. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is at each occurrence independently selected from
fluoro and NH 2 ,
wherein R 1b is hydrogen or C 1 -C 5 alkyl,
wherein the C 1 -C 5 alkyl is substituted with 0-3 hydroxyl.
12. The compound of claim 1 or a pharmaceutically acceptable salt thereof, of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), or Formula (If):
wherein W, L, R 1 , R 2 , R A , n and m are defined according to claim 1 ;
wherein W, L, R 1 , R 2 , R A , n and m are defined according to claim 1 ;
wherein L, R 1 , R 2 , R A , n and m are defined according to claim 1 ;
wherein L, R 1 , R 2 , R A , n and m are defined according to claim 1 ;
wherein L, R 1 , R 2 , R A and m are defined according to claim 1 ;
wherein L, R 1 , R 2 , R A and m are defined according to claim 1 .
13. A compound or a pharmaceutically acceptable salt thereof, selected from:
14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
15. A method of treating an ocular surface disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
16. The method of claim 15 , wherein the ocular surface disorder is selected from chronic ocular surface pain (COSP), dry eye disease, conjunctivitis, keratoconjuctivitis, vernal keratoconjunctivitis, allergic conjunctivitis, Meibomian gland dysfunction, thyroid eye disease, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies, LASIK induced corneal neuropathies, corneal dystrophies, epithelial basement membrane dystrophy, corneal erosions or abrasions, ocular surface diseases, blepharitis, meibomitis, glaucoma, conjunctivochalasis, keratopathis, keratitis, iritis, episclentis, corneal surgery, trichiasis, pterygium, xerophthalmia, and patients recovering from neurotrophic keratitis.
17. A method of treating ocular surface pain or ocular hyperemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
18. The method according to claim 17 , wherein the patient is suffering from one or more of dry eye disease, conjunctivitis, keratoconjuctivitis, vernal keratoconjunctivitis, allergic conjunctivitis, Meibomian gland dysfunction, thyroid eye disease, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies, LASIK induced corneal neuropathies, corneal dystrophies, epithelial basement membrane dystrophy, corneal erosions or abrasions, ocular surface diseases, blepharitis, meibomitis, glaucoma, conjunctivochalasis, keratopathis keratitis, iritis, episclentis, corneal surgery, trichiasis, pterygium, xerophthalmia, or patients recovering from neurotrophic keratitis.
19. A method of treating corneal induced pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 13 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
21. A method of treating ocular surface pain or ocular hyperemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 13 , or a pharmaceutically acceptable salt thereof.
22. A method of treating corneal induced pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 13 , or a pharmaceutically acceptable salt thereof.
23. A method of treating an ocular surface disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 13 , or a pharmaceutically acceptable salt thereof.
24. The method of claim 23 , wherein the ocular surface disorder is selected from chronic ocular surface pain (COSP), dry eye disease, conjunctivitis, keratoconjuctivitis, vernal keratoconjunctivitis, allergic conjunctivitis, Meibomian gland dysfunction, thyroid eye disease, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies, LASIK induced corneal neuropathies, corneal dystrophies, epithelial basement membrane dystrophy, corneal erosions or abrasions, ocular surface diseases, blepharitis, meibomitis, glaucoma, conjunctivochalasis, keratopathis, keratitis, iritis, episclentis, corneal surgery, trichiasis, pterygium, xerophthalmia, and patients recovering from neurotrophic keratitis.
25. A compound or a pharmaceutically acceptable salt thereof selected from:
(R)-1-(6-fluoro-5-((((1r,3R)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol; or
(S)-1-(6-fluoro-5-((((1r,3S)-3-(4-fluoro-3-(trifluoromethyl)phenoxy)cyclobutyl)amino)methyl)isoquinolin-8-yl)ethane-1,2-diol.
26. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 25 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
27. A method of treating ocular surface pain or ocular hyperemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 25 , or a pharmaceutically acceptable salt thereof.
28. A method of treating corneal induced pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 25 , or a pharmaceutically acceptable salt thereof.
29. A method of treating an ocular surface disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 25 , or a pharmaceutically acceptable salt thereof.
30. The method of claim 29 , wherein the ocular surface disorder is selected from chronic ocular surface pain (COSP), dry eye disease, conjunctivitis, keratoconjuctivitis, vernal keratoconjunctivitis, allergic conjunctivitis, Meibomian gland dysfunction, thyroid eye disease, keratoconus, ocular pain syndrome, Steven-Johnson's syndrome, corneal epitheliopathies, corneal neuropathies, LASIK induced corneal neuropathies, corneal dystrophies, epithelial basement membrane dystrophy, corneal erosions or abrasions, ocular surface diseases, blepharitis, meibomitis, glaucoma, conjunctivochalasis, keratopathis, keratitis, iritis, episclentis, corneal surgery, trichiasis, pterygium, xerophthalmia, and patients recovering from neurotrophic keratitis.